McKesson Rallies 6.6% as Analyst Raises Target to $1,070

The bull and bear cases are genuinely in tension here. Bulls point to McKesson's scale advantage, handling more than one-third of North American medication volumes with 99.9% order accuracy, and to a mix shift toward higher-margin specialty, oncology, and biosimilar channels. Management guided for 8% to 11% adjusted EBIT growth and 13% to 16% adjusted EPS growth from core businesses. Bears counter that the employer-sponsored coverage retreat is a real threat: GLP-1 prior authorizations represent an estimated 9.5% to 11.5% of RxTS segment revenue, 6% of large employers dropped coverage in 2026, and another 10% plan to follow in 2027. IRA Medicare price negotiations targeting roughly $28 billion of drug spend loom beyond that. The P/E multiple of 18.7x and EV/EBITDA of 14.0x leave little room for a miss if either of those pressures accelerates.

The short position offers no meaningful counter-signal to the bullish price action. Short interest is just 2.2% of the free float, and while it has ticked up 3.8% over the past week to roughly 2.73 million shares, that is a very small base. Borrowing costs are negligible at 0.45%, and availability is effectively unlimited, with over 75 million shares available to borrow relative to the short position. The lending market is completely open for bears who want exposure, but very few are taking it. The ORTEX short score of 32.8, edging higher from 30.5 a week ago but still well below mid-range, confirms that bearish conviction in the stock is structurally low. Options positioning is only slightly more cautious than usual: the put/call ratio is running at 0.80, just above its 20-day average of 0.77, a fraction of a standard deviation above the norm, not a defensive posture.

One alternative data point worth noting: Medicaid units reimbursed rose 78% year on year in Q1 2026 and have increased for three consecutive quarters, according to Centers for Medicare and Medicaid Services data tracked by ORTEX. None of the alt datasets for MCK have been measured to lead its reported financials, so this is context, not a signal about the next print. Still, the volume trend runs in the opposite direction to the bear case narrative about Medicaid exposure weighing on the business. Retail attention is also unusually high, with Wikipedia page views running at a z-score of 2.1 against MCK's own recent history as of late September, consistent with the share price recovery drawing broader notice.

Closely correlated peers COR and CAH both had positive weeks, up 2.9% and 4.3% respectively, so MCK's 6.6% move outpaced the group rather than simply riding a sector tide. The next scheduled catalyst is the Q2 earnings release on November 4, and with the stock now trading about 6% below the consensus price target, the question heading into that print is whether the specialty growth story can continue to offset the margin pressure that the bear case centres on.